Literature DB >> 16184353

[Recommendations of the DGRh on the therapy of Raynaud Syndrome (Zeitschrift für Rheumatologie, vol 64, March 2005) ].

C Fiehn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16184353     DOI： 10.1007/s00393-005-0761-1

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  5 in total

1.  Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine.

Authors:  B Coleiro; S E Marshall; C P Denton; K Howell; A Blann; K I Welsh; C M Black
Journal:  Rheumatology (Oxford)       Date:  2001-09       Impact factor: 7.580

Review 2.  Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis.

Authors:  A E Thompson; J E Pope
Journal:  Rheumatology (Oxford)       Date:  2004-11-16       Impact factor: 7.580

3.  [Recommendations of the German Society of Rheumatology on therapy of Raynaud syndrome and acral ulcerations].

Authors:  G Riemekasten
Journal:  Z Rheumatol       Date:  2005-03       Impact factor: 1.372

4.  Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.

Authors:  M Dziadzio; C P Denton; R Smith; K Howell; A Blann; E Bowers; C M Black
Journal:  Arthritis Rheum       Date:  1999-12

5.  Double-blind, placebo-controlled study of prazosin in Raynaud's phenomenon.

Authors:  H Wollersheim; T Thien; J Fennis; P van Elteren; A van 't Laar
Journal:  Clin Pharmacol Ther       Date:  1986-08       Impact factor: 6.875
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.